Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: a retrospective study from a single cancer center
Objective To investigate the role of consolidative thoracic radiation (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line chemo-immunotherapy followed by immunotherapy maintenance. Patients and methods Outcomes of patients without disease progression after first-line chemotherapy were retrospectively reviewed (January 2020 to December 2021). Based on TRT or not, patients were allocated to TRT group or non-TRT group. Progression-free survival (PFS), overall survival (OS) and local-recurrence free survival (LRFS) were calculated by the Kaplan–Meier method and compared by log-rank test. Results Of 100 patients, 47 received TRT and 53 non-TRT. The median follow-up was 20.3 months. The median PFS and OS in TRT were 9.1 months and 21.8 months, versus 8.8 months (p = 0.93) and 24.3 months (p = 0.63), respectively, in non-TRT. The median LRFS time in TRT was not reached, but significantly longer than 10.8 months in non-TRT (HR = 0.27, p < 0.01). Second-line chemotherapy significantly prolonged survival compared to that with chemo-free patients (mOS: 24.5 vs. 21.4 months, p = 0.026). The subgroup analysis showed a trend of patients with brain metastases benefit from TRT (21.8 versus 13.7 months, HR 0.61, p = 0.38) while liver metastases did not. Of 47 patients with TRT, only 10.6% of patients experienced grade 3 radiation-induced pneumonitis, while no grade 4 or 5 adverse events occurred. Conclusion Consolidative TRT in the period of immunotherapy maintenance followed first-line chemo-immunotherapy did not prolong OS and PFS but associated with improved LRFS in ES-SCLC..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Hormones and cancer - 14(2023), 1 vom: 04. Mai |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Yuying [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Immunotherapy |
---|
Anmerkungen: |
© The Author(s) 2023 |
---|
doi: |
10.1007/s12672-023-00666-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR050296647 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR050296647 | ||
003 | DE-627 | ||
005 | 20230505064745.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230505s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12672-023-00666-7 |2 doi | |
035 | |a (DE-627)SPR050296647 | ||
035 | |a (SPR)s12672-023-00666-7-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Yuying |e verfasserin |4 aut | |
245 | 1 | 0 | |a Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: a retrospective study from a single cancer center |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2023 | ||
520 | |a Objective To investigate the role of consolidative thoracic radiation (TRT) in extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line chemo-immunotherapy followed by immunotherapy maintenance. Patients and methods Outcomes of patients without disease progression after first-line chemotherapy were retrospectively reviewed (January 2020 to December 2021). Based on TRT or not, patients were allocated to TRT group or non-TRT group. Progression-free survival (PFS), overall survival (OS) and local-recurrence free survival (LRFS) were calculated by the Kaplan–Meier method and compared by log-rank test. Results Of 100 patients, 47 received TRT and 53 non-TRT. The median follow-up was 20.3 months. The median PFS and OS in TRT were 9.1 months and 21.8 months, versus 8.8 months (p = 0.93) and 24.3 months (p = 0.63), respectively, in non-TRT. The median LRFS time in TRT was not reached, but significantly longer than 10.8 months in non-TRT (HR = 0.27, p < 0.01). Second-line chemotherapy significantly prolonged survival compared to that with chemo-free patients (mOS: 24.5 vs. 21.4 months, p = 0.026). The subgroup analysis showed a trend of patients with brain metastases benefit from TRT (21.8 versus 13.7 months, HR 0.61, p = 0.38) while liver metastases did not. Of 47 patients with TRT, only 10.6% of patients experienced grade 3 radiation-induced pneumonitis, while no grade 4 or 5 adverse events occurred. Conclusion Consolidative TRT in the period of immunotherapy maintenance followed first-line chemo-immunotherapy did not prolong OS and PFS but associated with improved LRFS in ES-SCLC. | ||
650 | 4 | |a Small-cell lung cancer |7 (dpeaa)DE-He213 | |
650 | 4 | |a Thoracic radiation |7 (dpeaa)DE-He213 | |
650 | 4 | |a Immunotherapy |7 (dpeaa)DE-He213 | |
650 | 4 | |a Toxicity |7 (dpeaa)DE-He213 | |
650 | 4 | |a Survival |7 (dpeaa)DE-He213 | |
700 | 1 | |a Jing, Wang |4 aut | |
700 | 1 | |a Jing, Xuquan |4 aut | |
700 | 1 | |a Sun, Yulan |4 aut | |
700 | 1 | |a Tang, Xiaoyong |4 aut | |
700 | 1 | |a Guo, Jun |4 aut | |
700 | 1 | |a Zhang, Yan |4 aut | |
700 | 1 | |a Zhu, Hui |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Hormones and cancer |d New York, NY [u.a.] : Springer, 2010 |g 14(2023), 1 vom: 04. Mai |w (DE-627)SPR027077128 |w (DE-600)2543318-0 |x 1868-8500 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:04 |g month:05 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12672-023-00666-7 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 14 |j 2023 |e 1 |b 04 |c 05 |